drugset / Trial / NCT06898957
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Timeline
- Start
- 2025-05-16
- Primary completion
- 2031-06-23
- Completion
- 2031-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tarlatamab | Protein / enzyme biologic | — | Intravenous |
| Subject | YL201 | Other / unclassified | — | Intravenous |